Key Developments For Biolase Technology, Inc.
Biolase Technology, Inc. (BLTI.O) (Consolidated Issue listed on NASDAQ Capital Market)
Biolase Technology, Inc. Announces Revolutionary Gum Disease Treatment
Biolase Technology, Inc. announced that its new Deep Pocket Therapy with New Attachment using the Waterlase MD and patented Radial Firing Perio Tips (RFPT) for a non-surgical alternative treatment for moderate to advanced gum disease. The newly FDA cleared procedure for the Waterlase MD assists in new attachment, and in most cases provides deep pocket treatments in a single visit without the use of a scalpel, stitches or the conventional cutting of the gums. Traditional periodontal therapy for the treatment of deep pockets involves a surgical procedure where after scaling and root planning of the teeth, the gum tissue is cut with a scalpel and flapped back to expose the teeth and underlying disease which is removed with traditional dental instruments, followed by stitching the gums back into place. While treating deep pockets is considered critical for overall good health and the preservation of teeth, the invasive nature of the traditional procedure increases the anxiety many patients have for gum treatment. Many patients diagnosed with moderate to advanced pockets have avoided the procedure all together.
Biolase Technology, Inc. And Levin Group, Inc To Collaborate
Biolase Technology, Inc. announced that it has engaged Baltimore based Levin Group, Inc., a international dental practice consulting firm, to develop a practice management system for the successful integration and implementation of BIOLASE dental lasers into everyday dental offices. The practice management system will showcase the value of BIOLASE lasers as an effective technology that has been allowing dental practices to increase the number of services they provide and enhance the patient experience. This program will be designed to teach the dentist and dental team how to maximize the use of their laser and achieve an even higher positive return on investment.
Biolase Technology, Inc. Receives Approval In People's Republic of China To Sell Waterlase Dental Laser Systems
Biolase Technology, Inc. announced that it has received approval to sell its Waterlase dental laser systems in the People's Republic of China. The official medical device registration certificate granted by the Chinese State Food and Drug Agency comes to positive closure after many years of hard work, rigorous testing and analysis of the product.
Biolase Technology, Inc. Appoints Brett L. Scott As Chief Financial Officer
Biolase Technology, Inc. announced that Brett L. Scott has been appointed Chief Financial Officer (CFO), effective immediately. Fred Capallo served as interim Chief Financial Officer during this period of transition.
Biolase Technology, Inc. Issues Q2 2009 Revenue Outlook
Biolase Technology, Inc. announced that for second quarter of 2009, it expects net revenue exceeding $13.5 million.
